Leveraged Finance Fights Melanoma
2020 Event - Postponed
From the Event Co-Chairs: MRA is closely monitoring the progression of Coronavirus (COVID-19) and assessing the impact on all aspects of our work. In line with CDC recommendations, and out of concern for the health and well-being of our community, the Leveraged Finance Fights Melanoma (LFFM) event scheduled for May 20, 2020 at the Museum of Modern Art in NY is being postponed. We are working with the museum to secure a new date in the September-October timeframe, and will announce the new date as soon as it is determined.
LFFM is one of our biggest events of the year, and funds raised help us fulfill our mission – to end suffering and death from Melanoma. Cancer doesn’t stop, even during a pandemic, and support to advance critical research that accelerates progress and improves outcomes is needed now more than ever.
While we will miss gathering in May, we look forward to seeing you in the early Fall and coming together as a community to fight melanoma. Until then, stay safe and healthy.
Museum of Modern Art
18 West 54th Street
New York, NY
Add to calendar
2020 Event Chairs:
Clare Bailhé (Apollo MidCap), Brendan Dillon (UBS), Kerry Dolan (PSP Investments), Lee Grinberg (Elliott Management), George Mueller (KKR), AJ Murphy (Silver Lake), Geoff Oltmans (Silver Lake), Jeff Rowbottom (Iron Park Capital), Ian Schuman (Latham & Watkins), Cade Thompson (KKR), & Trevor Watt (Hellman & Friedman)
Spotlighted in publications like Forbes, Bloomberg and The New York Times, the Leveraged Finance Fights Melanoma (LFFM) event has become the premier gathering of professionals from the leveraged finance, private equity, and investment communities who come together to fight melanoma, the deadliest form of skin cancer. Some of the most prominent names in the industry —Carl Icahn, Mike Milken, Leon Black, Henry Kravis and Howard Marks—have been featured.
The annual event raises critical funds for melanoma research and awareness on skin cancer prevention. Founded in 2011 by Jeffrey Rowbottom of PSP Investments and Brendan Dillon of UBS—both of whom combatted melanoma— the LFFM event has raised more than $10.6 million that goes directly to research.
Advances in melanoma research supported by MRA have changed the landscape dramatically for patients, with 12 of the 14 treatment options coming to market since the event’s kick-off. These advances have created a ripple effect across the field of oncology. Drugs first approved in melanoma are now being tested in more than 30 cancers.